Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients. KondiliLoreta A. GaetaGiovanni Battista IeluzziDonatella Linda ZignegoAnna MontiMonica GoriAndrea SoriaAlessandro RaimondoGiovanni FilomiaRoberto Di LeoAlfredo IannoneAndrea MassariMarco CorsiniRomina GulminettiRoberto CominiAlberto Gatti ToniuttoPierluigi DissegnaDenis RussoFrancesco Paolo ZanettoAlberto Grazia RumiMaria BrancaccioGiuseppina DanieliElena Rossana BrunettoMaurizia WeimerLiliana Elena Giovanna QuarantaMaria VellaStefano PuotiMassimo 2017 <p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p>